Inozyme Pharma, Inc.
NASDAQ: INZY0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Douglas A. Treco
- Employees
- 67
- Headquarters
- Boston, United States
- IPO year
- 2020
- Market cap
- $258.2M
- Website
- https://www.inozyme.com
Loading INZY…
Loading profile data…Frequently asked questions about INZY
What does Inozyme Pharma, Inc. (INZY) do?
Inozyme Pharma, Inc. operates as a biopharmaceutical entity dedicated to addressing rare diseases. Its primary mission involves pioneering treatments for disorders characterized by aberrant mineralization, which impacts the body's vascular system, soft tissues, and skeletal structure. The company's flagship therapeutic candidate, INZ-701, is an...
Where does INZY trade?
Inozyme Pharma, Inc. (INZY) trades on the NASDAQ Global Select.
What sector is INZY in?
Inozyme Pharma, Inc. (INZY) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Inozyme Pharma, Inc.?
Douglas A. Treco is the chief executive officer of Inozyme Pharma, Inc. (INZY).
Where is Inozyme Pharma, Inc. headquartered?
Inozyme Pharma, Inc. is headquartered in United States.
Does INZY pay a dividend?
Inozyme Pharma, Inc. (INZY) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did INZY go public?
Inozyme Pharma, Inc. (INZY) completed its initial public offering in 2020.